An announcement from Insulet ( (PODD) ) is now available.
On March 20, 2025, Insulet Corporation closed its issuance and sale of $450 million in 6.50% Senior Notes due 2033, with net proceeds expected to be approximately $444 million. Additionally, Insulet entered into a Seventh Amendment to its Credit Agreement, extending the maturity of revolving credit commitments to March 20, 2030, and increasing the commitments to $500 million. The company also engaged in Note Repurchase Transactions, repurchasing $419 million of its Convertible Senior Notes due 2026, which will impact its outstanding debt and potentially influence stock market activities.
More about Insulet
Insulet Corporation operates in the medical device industry, primarily focusing on the development and sale of innovative insulin delivery systems. The company is known for its Omnipod Insulin Management System, which offers a tubeless, wearable insulin pump for individuals with diabetes.
YTD Price Performance: 3.49%
Average Trading Volume: 668,750
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $18.29B
For detailed information about PODD stock, go to TipRanks’ Stock Analysis page.